Himachal Pradesh high court restrains DRL from selling BI’s diabetic drug Jardiance

Dr Reddy’s on Thursday said Himachal Pradesh high court has issued an interim injunction restraining them from manufacturing and selling generic version of German drug maker Boehringer Ingelheim‘s (BI) diabetes drug Jardiance.

The drugmaker said it is reviewing legal options including filing an appeal against the court order.

Dr Reddy’s has launched copies of Jardiance (empagliflozin), which has valid patent in India until 2025. BI has sought restraining order on manufacture and sale of the drug.

Jardiance is top-selling drug for BI in India.

  • Related Posts

    The Most Innovative Medical Devices of 2026: Breakthrough Technologies Target Heart Disease, Cancer, Neurological Disorders and Kidney Dysfunction

    NEW DELHI: Medical technology innovation is entering a new phase, with advanced cardiac implants, incisionless brain surgery, blood-based cancer screening, smart insulin delivery and real-time kidney-function monitoring among the technologies…

    Three arrested after liquor bottles found at pharma firm

    Patna: Three people were arrested and sent to jail after a large quantity of liquor bottles was found at Cellulas Pharma Private Limited in Kankarbagh during a raid by the…

    Leave a Reply

    Your email address will not be published. Required fields are marked *

    You Missed

    The Most Innovative Medical Devices of 2026: Breakthrough Technologies Target Heart Disease, Cancer, Neurological Disorders and Kidney Dysfunction

    The Most Innovative Medical Devices of 2026: Breakthrough Technologies Target Heart Disease, Cancer, Neurological Disorders and Kidney Dysfunction

    Three arrested after liquor bottles found at pharma firm

    Three arrested after liquor bottles found at pharma firm

    NEXUS 2026 brings pharma experts together to explore next generation analytical technologies

    NEXUS 2026 brings pharma experts together to explore next generation analytical technologies

    National Formulary of India 2026 Lists Unapproved Drugs; DCGI Seeks Urgent Explanation from IPC Over Regulatory Discrepancy

    National Formulary of India 2026 Lists Unapproved Drugs; DCGI Seeks Urgent Explanation from IPC Over Regulatory Discrepancy

    Six leading mental health organisations unite to launch ‘Humanising Medicine India Initiative’ on World Mental Health Day

    Six leading mental health organisations unite to launch ‘Humanising Medicine India Initiative’ on World Mental Health Day

    Cancer Drug Prices May Fall By Up To 70% As Government Caps Trade Margins: Sources

    Cancer Drug Prices May Fall By Up To 70% As Government Caps Trade Margins: Sources